Abstract
Background Adefovir and tenofovir are nucleotide analogues used as long-term therapy of chronic hepatitis B. Side effects are few, but prolonged and high-dose therapy has been associated with proximal renal tubular dysfunction (RTD). Aim To assess the incidence of RTD during long-term nucleotide therapy of chronic hepatitis B. Methods A total of 51 patients being treated at the Clinical Center, National Institutes of Health were studied. Diagnosis of RTD required de novo appearance of at least three of five features: hypophosphataemia, hypouricaemia, serum creatinine elevation, proteinuria or glucosuria. Results Among 51 patients treated for 1-10 (mean 7.4) years with adefovir (n = 42), tenofovir (n = 4) or adefovir followed by tenofovir (n = 5), 7 (14%) developed RTD. Time to onset ranged from 22 to 94 (mean 49) months with an estimated 10-year cumulative rate of 15%. All seven had low urinary percent maximal tubular reabsorption of phosphate (
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1317-1325 |
| Number of pages | 9 |
| Journal | Alimentary Pharmacology and Therapeutics |
| Volume | 35 |
| Issue number | 11 |
| DOIs | |
| State | Published - Jun 2012 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
Cite this
Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. / Gara, N.; Zhao, X.; Collins, M. T.; Chong, W. H.; Kleiner, D. E.; Jake Liang, T.; Ghany, M. G.; Hoofnagle, J. H.
In: Alimentary Pharmacology and Therapeutics, Vol. 35, No. 11, 06.2012, p. 1317-1325.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B
AU - Gara, N.
AU - Zhao, X.
AU - Collins, M. T.
AU - Chong, W. H.
AU - Kleiner, D. E.
AU - Jake Liang, T.
AU - Ghany, M. G.
AU - Hoofnagle, J. H.
PY - 2012/6
Y1 - 2012/6
N2 - Background Adefovir and tenofovir are nucleotide analogues used as long-term therapy of chronic hepatitis B. Side effects are few, but prolonged and high-dose therapy has been associated with proximal renal tubular dysfunction (RTD). Aim To assess the incidence of RTD during long-term nucleotide therapy of chronic hepatitis B. Methods A total of 51 patients being treated at the Clinical Center, National Institutes of Health were studied. Diagnosis of RTD required de novo appearance of at least three of five features: hypophosphataemia, hypouricaemia, serum creatinine elevation, proteinuria or glucosuria. Results Among 51 patients treated for 1-10 (mean 7.4) years with adefovir (n = 42), tenofovir (n = 4) or adefovir followed by tenofovir (n = 5), 7 (14%) developed RTD. Time to onset ranged from 22 to 94 (mean 49) months with an estimated 10-year cumulative rate of 15%. All seven had low urinary percent maximal tubular reabsorption of phosphate (
AB - Background Adefovir and tenofovir are nucleotide analogues used as long-term therapy of chronic hepatitis B. Side effects are few, but prolonged and high-dose therapy has been associated with proximal renal tubular dysfunction (RTD). Aim To assess the incidence of RTD during long-term nucleotide therapy of chronic hepatitis B. Methods A total of 51 patients being treated at the Clinical Center, National Institutes of Health were studied. Diagnosis of RTD required de novo appearance of at least three of five features: hypophosphataemia, hypouricaemia, serum creatinine elevation, proteinuria or glucosuria. Results Among 51 patients treated for 1-10 (mean 7.4) years with adefovir (n = 42), tenofovir (n = 4) or adefovir followed by tenofovir (n = 5), 7 (14%) developed RTD. Time to onset ranged from 22 to 94 (mean 49) months with an estimated 10-year cumulative rate of 15%. All seven had low urinary percent maximal tubular reabsorption of phosphate (
UR - http://www.scopus.com/inward/record.url?scp=84860519158&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860519158&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2036.2012.05093.x
DO - 10.1111/j.1365-2036.2012.05093.x
M3 - Article
C2 - 22506503
AN - SCOPUS:84860519158
VL - 35
SP - 1317
EP - 1325
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
SN - 0269-2813
IS - 11
ER -